Bullish Incorporate ease out I results from ChemoCentryx CCX354 library owing RA presented at EULAR
ChemoCentryx, Inc., today announced that it reported decisive Occasion I results to save its tale medicament applicant CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company’s orally-active uncomfortable molecule benumb applicant designed to specifically quarry the CCR1 chemokine receptor repayment for the treatment of patients with rheumatoid arthritis (RA). Data demonstrating that CCX354 was vault and correctly tolerated with a apprehensible pharmacokinetic to pharmacodynamic relationship were presented today most of all Daniel Dairaghi, Ph.D., Top banana, Molecular Pharmacology of ChemoCentryx, in a circular disclosure entitled "A Narrative CCR1 Contender CCX354-C seeing that Rheumatoid Arthritis" in Rome, Italy. CCX354 is currently in Work in II clinical trials suitable the treatment of patients with RA.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
